6-K - GSK - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2020

Commission File Number 001-15170

GlaxoSmithKline plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GlaxoSmithKline plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them<br>(‘PCA’)
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial<br>notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 25 pence each (‘Ordinary<br>Shares’)<br><br><br>ISIN: GB0009252882
b)	Nature<br>of the transaction	Acquisition<br>of Ordinary Shares following the exercise of options granted on 30<br>November 2016 at the option price of 12.95 per Ordinary Share<br>under the Company’s ShareSave Plan.
c)	Price(s)<br>and volume(s)	Price(s)
		12.95
d)	Aggregated<br>information<br><br><br>Aggregated<br>volume Price	N/A (single transaction)
e)	Date<br>of the transaction	2020-06-12
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GlaxoSmithKline plc
	(Registrant)
Date: June<br>16, 2020
	By:/s/ VICTORIA<br>WHYTE<br><br><br>--------------------------
	Victoria Whyte
	Authorised<br>Signatory for and on
	behalf<br>of GlaxoSmithKline plc